12P - EGFR gene mutation in advanced non-small cell lung cancer - a case series
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Non-Small-Cell Lung Cancer, Metastatic
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
Molecular targeted therapy based on TKIs, directed at the Epidural growth factor receptor (EGFR) is one of the recent options for the management of advanced Non-Small Cell Lung Cancer (NSCLCs). EGFR gene mutations, exon 19 deletions (LREA deletions) and exon 21 (L858R) are most common and good predictions of response to EGFR-TKI treatment. EGFR gene mutations are found in approximately 10% of Caucasian patients and up to 50% of Asian populations. Recent studies have endorsed these incidences in European and Asian populations. The frequency of EGFR mutation is higher in non-smokers and in women. To objective of this study was to determine the frequency of EGFR gene mutations in non–small-cell lung cancer patient presenting at our institute.